Dupilumab efficacy in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis and clinical characteristics of early super-responders. (PubMed, BMC Pediatr) - Oct 22, 2026 - "Dupilumab demonstrates significant efficacy and a favorable safety profile in the treatment of moderate-to-severe atopic dermatitis in children aged 6 months to 6 years. During treatment, patients presented alleviated allergic comorbidities, decreased incidence of recurrent upper respiratory tract infections, and improved quality of life for children and their families. Elevated absolute basophil count in peripheral blood and the presence of allergic rhinitis were independent predictors of eSR to dupilumab in children with AD."
Journal • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Food Hypersensitivity • Immunology • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • Pruritus • Pulmonary Disease • Respiratory Diseases
|
|
Li Ma; Li Xia; Mengjun Wei; Miaomiao Zhao; Nan Yu; Peiyao Yu; Wenjia Mou; Xiaoyu Jia; Yuanyuan Shang
|